A diamminedichloroplatinum compound in which the two ammine ligands and two chloro ligands are oriented in a cis planar configuration around the central platinum ion. An anticancer drug that interacts with, and forms cross-links between, DNA and proteins, it is used as a neoplasm inhibitor to treat solid tumours, primarily of the testis and ovary. Commonly but incorrectly described as an alkylating agent due to its mechanism of action (but it lacks alkyl groups).
Chemical ID:
MESH:D002945
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cisplatin results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Cisplatin results in increased phosphorylation of MAPK1 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole promotes the reaction [Cisplatin results in increased phosphorylation of and results in increased activity of MAPK1 protein]; [chrysin co-treated with Cisplatin] results in increased phosphorylation of MAPK1 protein; [Cisplatin co-treated with Quercetin] results in decreased phosphorylation of MAPK1 protein; [Cisplatin results in decreased susceptibility to Cisplatin] which results in decreased phosphorylation of MAPK1 protein; [Curcumin results in decreased activity of MAPK1 protein] which results in increased susceptibility to Cisplatin; [Sorafenib co-treated with Cisplatin] results in decreased phosphorylation of MAPK1 protein; astilbin inhibits the reaction [Cisplatin results in increased phosphorylation of MAPK1 protein]; Cisplatin results in increased phosphorylation of and results in increased activity of MAPK1 protein; Fluorouracil inhibits the reaction [Cisplatin results in increased phosphorylation of MAPK1 protein]; hesperetin inhibits the reaction [Cisplatin results in increased phosphorylation of MAPK1 protein]; mirdametinib inhibits the reaction [Cisplatin results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Nicotine inhibits the reaction [Cisplatin results in increased activity of MAPK1 protein]; U 0126 analog inhibits the reaction [Cisplatin results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Cisplatin results in increased activity of MAPK1 protein]; U 0126 inhibits the reaction [Cisplatin results in increased phosphorylation of and results in increased activity of MAPK1 protein]; U 0126 inhibits the reaction [Cisplatin results in increased phosphorylation of MAPK1 protein]
anemoside B4 inhibits the reaction [Cisplatin results in increased phosphorylation of MAPK1 protein]; aucubin inhibits the reaction [Cisplatin results in increased phosphorylation of MAPK1 protein]; bicyclol inhibits the reaction [Cisplatin results in increased phosphorylation of MAPK1 protein]; Catechin inhibits the reaction [Cisplatin results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Cisplatin results in increased phosphorylation of and results in increased activity of MAPK1 protein; hesperetin inhibits the reaction [Cisplatin results in increased phosphorylation of MAPK1 protein]; IL6 inhibits the reaction [Cisplatin results in increased phosphorylation of MAPK1 protein]; madecassoside inhibits the reaction [Cisplatin results in increased phosphorylation of MAPK1 protein]; N-acetyl glycine cysteine amide inhibits the reaction [Cisplatin results in increased phosphorylation of MAPK1 protein]; N-acetyl-Cys-Gly-Pro-Cys-amide inhibits the reaction [Cisplatin results in increased phosphorylation of MAPK1 protein]; Oleanolic Acid inhibits the reaction [Cisplatin results in increased phosphorylation of MAPK1 protein]; PRKCD affects the reaction [Cisplatin results in increased activity of MAPK1 protein]
